Man Group’s Compass Therapeutics CMPX Stock Holding History

Man Group’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-25,305	Closed	-$99.3K	–	1932
2022 Q4	$127K	Buy	+25,305	New	+$101K	﹤0.01%	1871

Other funds holding CMPX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Man Group's CMPX Position: Q1 2023 in Review

Man Group sold out of Compass Therapeutics (CMPX) in Q1 2023, closing a stake of 25,305 shares — an estimated $99.3K sold.

Man Group first reported a position in CMPX in Q4 2022 and held it in 1 quarter. The position peaked at $127K in Q4 2022. 72 funds tracked by Wall St. Rank hold CMPX as of Q1 2023.

Man Group reported no remaining Compass Therapeutics position as of Q1 2023 after selling out during the quarter.
Man Group sold 25,305 Compass Therapeutics shares in Q1 2023, an estimated $99.3K.
Man Group first reported a position in Compass Therapeutics in Q4 2022 and held it in 1 quarter.
Man Group's Compass Therapeutics position peaked at $127K in Q4 2022.
72 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.